TCM
SLN

TCG Crossover Management’s Silence Therapeutics SLN Stock Holding History

TCG Crossover Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Hold
3,033,560
– – 0.46% 37
2025
Q4 		$18.4M Hold
3,033,560
– – 0.61% 33
2025
Q3 		$15.7M Hold
3,033,560
– – 0.77% 28
2025
Q2 		$17.6M Hold
3,033,560
– – 2.01% 21
2025
Q1 		$8.55M Hold
3,033,560
– – 1.17% 27
2024
Q4 		$20.9M Hold
3,033,560
– – 2.04% 23
2024
Q3 		$55.2M Sell
3,033,560
-261,790
-8% -$4.87M 4.67% 6
2024
Q2 		$62.6M Hold
3,295,350
– – 6.53% 4
2024
Q1 		$71.2M Buy
3,295,350
+1,190,475
+57% +$25.9M 5.63% 4
2023
Q4 		$36.6M Hold
2,104,875
– – 4.05% 12
2023
Q3 		$20.7M Hold
2,104,875
– – 3.04% 15
2023
Q2 		$11.6M Hold
2,104,875
– – 1.9% 15
2023
Q1 		$13.1M Hold
2,104,875
– – 2.54% 14
2022
Q4 		$32.1M Hold
2,104,875
– – 5.67% 6
2022
Q3 		$21.1M Buy
+2,104,875
New +$22.2M 6.34% 5

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TCG Crossover Management's SLN Position: Q1 2026 in Review

TCG Crossover Management held its Silence Therapeutics (SLN) position steady in Q1 2026 at 3,033,560 shares worth $16M. The position accounts for 0.46% of the portfolio, ranked #37.

TCG Crossover Management first reported a position in SLN in Q3 2022 and has held it in 15 quarters since. The position peaked at $71.2M in Q1 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • TCG Crossover Management held 3,033,560 shares of Silence Therapeutics worth $16M as of Q1 2026.
  • TCG Crossover Management left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up 0.46% of TCG Crossover Management's portfolio in Q1 2026, its #37 holding.
  • TCG Crossover Management first reported a position in Silence Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • TCG Crossover Management's Silence Therapeutics position peaked at $71.2M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.